In recent years, immune checkpoint inhibitors (ICIs), which target cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed cell death 1 (PD-1) and programmed cell death ligand-1 (PD-L1), have shown significant efficacy in treating various malignant tumors. This evidence concerns the gene PDCD1 and cancer.